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Chromodomain Helicase DNA binding protein 5
(CHD5) is a tumor suppressor mapping to 1p36,
a genomic region that is frequently deleted in human
cancer. Although CHD5 belongs to the CHD family of
chromatin-remodeling proteins, whether its tumor-
suppressive role involves an interaction with chro-
matin is unknown. Here we report that Chd5 binds
the unmodified N terminus of H3 through its tandem
plant homeodomains (PHDs). Genome-wide chro-
matin immunoprecipitation studies reveal preferen-
tial binding of Chd5 to loci lacking the active mark
H3K4me3 and also identify Chd5 targets implicated
in cancer. Chd5 mutations that abrogate H3 binding
are unable to inhibit proliferation or transcriptionally
modulate target genes, which leads to tumorigenesis
in vivo. Unlike wild-type Chd5, Chd5-PHD mutants
are unable to induce differentiation or efficiently sup-
press the growth of human neuroblastoma in vivo.
Our work defines Chd5 as an N-terminally unmodi-
fied H3-binding protein and provides functional
evidence that this interaction orchestrates chro-
matin-mediated transcriptional programs critical for
tumor suppression.
INTRODUCTION
Rearrangements of the short arm of human chromosome 1 occur
frequently in a variety of human cancers, with 1p36 deletion
being a prevalent lesion (Bagchi and Mills, 2008). We previously
identified Chromodomain Helicase DNA binding protein 5
(CHD5) as a tumor suppressor mapping to 1p36, and discovered
that it is frequently deleted in human glioma (Bagchi et al., 2007).
Recent studies have indicated that in addition to being
commonly deleted, CHD5 is epigenetically silenced (Koyama
et al., 2012; Mokarram et al., 2009; Mulero-Navarro and Esteller,
2008; Wang et al., 2009b; Zhao et al., 2011) or mutated (Agrawal92 Cell Reports 3, 92–102, January 31, 2013 ª2013 The Authorset al., 2011; Berger et al., 2011; Gorringe et al., 2008; Jones et al.,
2010; Lang et al., 2011; Li et al., 2011; Okawa et al., 2008; Rob-
bins et al., 2011; Sjo¨blom et al., 2006; Cancer Genome Atlas
Research Network, 2008, 2011) in a variety of human cancers.
CHD5 expression is also a favorable predictor of survival
following anticancer therapy (Du et al., 2012; Garcia et al.,
2010; Koyama et al., 2012; Wong et al., 2011).
CHD5 is a member of the CHD protein family, a group of nine
proteins (CHD1–CHD9) that are defined by dual chromodomains
as well as SWI/SNF-like ATP-dependent helicase motifs (Mar-
fella and Imbalzano, 2007; Sims and Wade, 2011). For CHD1,
these motifs have been implicated in nucleosome mobilization
(Lusser et al., 2005). CHD proteins have been shown to mediate
transcriptional activation, repression, and elongation (Murawska
and Brehm, 2011). Although some chromodomains bind methyl-
ated histones (Flanagan et al., 2005; Jacobs and Khorasaniza-
deh, 2002; Nielsen et al., 2002), the chromodomains of CHD4
do not bind histone tails, but instead bind DNA directly (Boua-
zoune et al., 2002). CHD5, like its closest members CHD3 and
CHD4, has tandem plant homeodomains (PHDs; Figure 1A).
Growing evidence implicates PHDs as readers of specifically
modified or unmodified histones (Godfried et al., 2002; Koh
et al., 2008; Lan et al., 2007; Mansfield et al., 2011; Matthews
et al., 2007; Musselman et al., 2009, 2012; Ooi et al., 2007;
Org et al., 2008; Rajakumara et al., 2011; Saksouk et al., 2009;
Shi et al., 2006, 2007; Tsai et al., 2010; Wang et al., 2009a; Wy-
socka et al., 2006). The PHD-mediated histone interaction
appears to be functionally important because its perturbation
is associated with various human diseases, including immuno-
logical disorders, neurological syndromes, and cancer (Baker
et al., 2008).
Given CHD5’s pivotal role in human cancer, we sought to
elucidate its mechanism of tumor suppression by determining
the ability of its PHDs to bind specific histone marks. Here we
demonstrate that the dual PHDs of Chd5 mediate binding
specifically to the N terminus of H3 lacking posttranslational
modifications, and define this interaction as being essential for
Chd5 to inhibit cellular proliferation, modulate gene expression,
induce differentiation, and effectively suppress tumorigenesis
in vivo.
Figure 1. PHDs Mediate Binding of Chd5
with the N Terminus of Unmodified H3
(A) Schematic diagram of mouse Chd5: HMG-box
(161–201), PHD1 (345–403), PHD2 (408–465),
Chromodomains (468–646), DNA/RNA helicase C
(700–1,140), Homeodomain-like (1,425–1,481),
CHD-C2 (1,728–1,901). Numbers in parentheses
depict amino acid number.
(B) Histone peptide array probed with GST-Chd5-
PHD1+2; red spots (left) and corresponding
red text (right) indicate GST-specific signals. a,
asymmetric; ac, acetylation; H, histone; me,
methylation; ph, phosphorylation; s, symmetric.
(C) Peptide pull-down assays with biotinylated
histone peptides and recombinant tandem PHDs
of Chd5. Chd5 PHDs bind the unmodified H3 (1-
21) peptide; trimethylation of H3K4 (but not H3K9)
disrupts binding.
(D) Peptide pull-down assays with biotinylated H3
peptides and nuclear extracts prepared from WT
adult mouse brain, followed by immunoblotting
with an anti-Chd5 antibody, show preferential
binding with H3K4me0.
(E) Coimmunofluorescence indicates that Chd5
(red) and H3K4me3 (green) do not overlap (Pear-
son coefficient of correlation ranges from0.01 to
0.12). Cherry-tagged Chd5 expressed in MEFs
(upper panels) and endogenous Chd5 immuno-
stained with anti-Chd5 antibody (lower panels).
Scale bar: 15 mm.
(F) The majority of Chd5 peaks identified by ChIP-
seq lie within 2 kb of a TSS.
(G) Themajority (67.2%) of nucleotides that map to
H3K4me3 and Chd5 peaks do not overlap.
(H) Only 38% (represented by the gray box) of
Chd5 and H3K4me3 overlapping peaks are within
100 bp of each other. Negative or positive distance
indicates that the H3K4me3 peak is upstream
or downstream, respectively, of the Chd5 peak
relative to the transcriptional orientation of the
gene. The distribution is skewed toward Chd5-
bound peaks being upstream of the H3K4me3-
bound peaks (positive distance), i.e., away from
the gene body.
See also Figure S1, Table S1, and Table S2.RESULTS
Chd5-PHDs Bind the N Terminus of Unmodified H3
We screened histone peptide arrays with tagged purified poly-
peptides encompassing the tandem PHDs of Chd5 and identi-
fied specific binding with N-terminally unmodified H3 peptides
(unmodified residues 2, 3, and 4 of H3; Figures 1B and S1A).
We confirmed the specificity of PHD interactions with unmodi-
fied H3, H3K4me1, H3K4me2, and H3K4me3 using in vitro
peptide pull-down assays (Figure 1C). Similar assays using indi-
vidual PHDs indicated that although PHD1 and PHD2 had the
same binding preference for H3K4me0, PHD2 had the highestCell Reports 3, 92–10affinity (Figures S1B and S1C). Endoge-
nous Chd5 also bound preferentially to
H3K4me0 and did not bind to H3K4me3,
a mark that is characteristic of transcrip-tionally active genes (Figures 1D and S1D). In agreement with
a previous report that PHDs of both CHD5 (Oliver et al., 2012)
and its close family member CHD4 bind N-terminally unmodified
H3 (Musselman et al., 2012), our findings indicate that the PHDs
of Chd5 bind to unmodified H3, and that this interaction is dis-
rupted by posttranslational modifications of extreme N-terminal
residues of H3.
Chd5 Preferentially Binds Genomic Loci Lacking the
Active Mark H3K4me3
Given that our in vitro data indicate that Chd5-PHDs do not bind
H3K4me3, we asked whether the subnuclear pattern of Chd5 is2, January 31, 2013 ª2013 The Authors 93
reciprocal to that of H3K4me3. Using immunofluorescence in
primary mouse embryonic fibroblasts (MEFs), we found Chd5
expressed in two different patterns: in small dots throughout
the nucleus, or in a punctate pattern overlapping with DAPI-en-
riched regions (Figure 1E). Expression analyses indicated that
whereas Chd5 and H3K4me3 did not significantly overlap, the
punctate pattern of Chd5 overlapped with H3K9me3, a mark of
heterochromatin (Figures S1E–S1G).
To determine whether this inverse correlation between Chd5
and H3K4me3 was evident at the genomic level, we used chro-
matin immunoprecipitation followed by DNA sequencing (ChIP-
seq) to identify Chd5-bound and H3K4me3-bound loci, and
compared their correlations across the genome. Annotation of
peaks to Refseq genes indicated that the majority (61.7%) of
Chd5-bound peaks were within 2 kilobase (kb) of the transcrip-
tion start site (TSS) of known genes (Figures 1F and S1H).
Because H3K4me3 preferentially marks TSS (Barski et al.,
2007), we restricted our analysis to high-confidence peakswithin
this interval (Table S1; accession number SRA062358). The
majority (63.5%) of these gene-proximal Chd5-peaks mapped
to genes lacking H3K4me3-peaks (Figure S1I). Out of the large
fraction of genes whose TSS overlaps with H3K4me3 peaks,
there was a depletion of Chd5 peaks that was 1.2-fold less
than what would be expected randomly. Because of the small
number of Chd5-bound regions, this depletion was just over
the threshold for statistical significance (p < 0.08, corrected
Fisher; Table S2). When the nucleotide sequence of the peaks
was considered, only 32.8% of the nucleotides overlapped
between H3K4me3-enriched region reads and Chd5-peaks (Fig-
ure 1G). Out of the small percentage of peaks mapping to the
same vicinity (36.5%; see Figure S1I), the majority (62%) were
spaced >100 nucleotides from each other, and most of the
peaks were oriented such that the Chd5-peak was upstream of
the H3K4me3-peak (Figures 1H and S1I). The read counts and
ChIP quantitative PCR (qPCR) analysis in the vicinity of several
representative Chd5-bound genes indicate that most Chd5-
bound loci lack H3K4me3 (Figures S1J and S1K). These data
indicate that the majority of Chd5-bound loci lack H3K4me3
in vivo, in agreement with our in vitro findings.
Mutation of Specific Conserved PHD Residues
Abrogates the Chd5-H3 Interaction
To identify Chd5-PHD residues that are important for the interac-
tion with unmodified H3, we compared the PHDs of Chd5 with
the PHDs of the closest family members, Chd3 and Chd4 (Fig-
ure 2A). We used site-specific mutagenesis to generate a series
of full-length Chd5 constructs with mutations in individual
conserved PHD residues, including some amino acids corre-
sponding to those that were previously characterized for human
CHD4 (Mansfield et al., 2011; Musselman et al., 2009, 2012; Fig-
ure 2B). Chromatin fractions from cells expressing Flag-tagged
Chd5 indicated that wild-type (WT) Chd5, as well as versions
of Chd5 with single amino acid mutations, is associated with
chromatin (Figure S2A). However, in vitro assays with unmodi-
fied H3 peptides and with either purified Chd5-PHDs (Figures
2C, 2D, S2B, and S2C) or nuclear lysates expressing Flag-
tagged Chd5 (WT or those with single amino acid mutations;
Figures 2E and S2D) indicated that several Chd5 residues are94 Cell Reports 3, 92–102, January 31, 2013 ª2013 The Authorscritical for facilitating the H3 interaction. These analyses suggest
that PHD1-D346A, PHD2-E414A, and PHD2-E419A bind H3
more efficiently than PHD1-D361A, PHD2-D434A, and PHD2-
D415A.
The Chd5-H3 Interaction is Critical for Chd5’s Ability
to Inhibit Cellular Proliferation
To determine whether PHD-mediated binding to H3 is function-
ally important for Chd5 activity, we compared full-length WT
Chd5 with Chd5-PHD mutants in terms of their ability to inhibit
cellular proliferation. WT Chd5 proved to be such a potent inhib-
itor of proliferation that it was necessary to express it in a regu-
lated fashion; therefore, we developed a tetracycline-inducible
system (Zuber et al., 2011) by expressing WT and mutant
Chd5 in primary Rosa reverse tetracycline transactivator (rtTA)-
expressing MEFs (Figures S3A–S3C). Whereas doxycycline
(dox) treatment of vector-expressing MEFs had no significant
effect (Figure S3D), dox-induced expression of WT Chd5 in-
hibited proliferation (Figure 3A), consistent with our previous
findings that proliferation is compromised in MEFs derived
from mice engineered to have an extra copy of the genomic
region encompassing Chd5 (Bagchi et al., 2007).
To functionally define residues that are critical for inhibiting
proliferation, we assayed a series of Chd5-PHDmutants for their
effect on proliferation using the dox-inducible system. Whereas
inducible expression of the H3-binding-competent Chd5-PHD
mutants D346A or W384A inhibited proliferation to an extent
comparable to that observed for WT Chd5, Chd5 mutants that
are compromised for H3 binding (G355A, D361A, D415A,
C432W, and D434A) were defective in their ability to inhibit
proliferation (Figures 3A and S3D). Whereas D346A inhibited
proliferation, this was not the case in the context of a second
mutation at D434, indicating that perturbation of a single PHD-
H3 interaction in one PHD overrides the ability of the other
PHD to compensate. These findings indicate that PHD-mediated
binding to unmodified H3 is essential for Chd5 to inhibit
proliferation.
Chd5 Transcriptionally Modulates Genes Implicated
in Cancer, whereas H3-Binding-Incompetent Chd5-PHD
Mutants Fail to Do So
Genome-wide ChIP-seq analysis indicated that the majority of
Chd5-bound peaks were located in promoters, 50 untranslated
regions (UTRs), and early introns (see Figures 1F and S1H),
supporting the idea that Chd5 plays a role in transcriptional
modulation. Pathway analysis of the candidate Chd5-modulated
genes identified by ChIP-seq showed enrichment for proteins
implicated in cancer (Figure 3B; Tables S3 and S4). To validate
specific candidate genes as being Chd5 modulated, we
analyzed their expression in primary MEFs in which Chd5 was
overexpressed or knocked down (Figures 3C and S3E). Indeed,
expression of several Chd5 targets correlated with Chd5 expres-
sion. Whereas mutants D346A and W384A were able to inhibit
both the proliferation and expression of several Chd5-bound
genes,mutant versions of Chd5 that were defective in their ability
to inhibit proliferation (G355A, D361A, D434A, and C432W) were
not able to inhibit expression of Chd5-bound loci. These findings
indicate that PHD-mediated H3 binding is critical for the ability of
Figure 2. Characterization of the PHD-
Histone Interaction
(A)Multiple sequence alignment of PHDs ofmouse
Chd5, Chd4, and Chd3. The zinc-binding residues
(yellow) and the Chd5-PHD residues that were
mutated (green and purple) are depicted.
(B) Mutant residues (green and purple) are map-
ped on the CHD4-PHD1 structure (2L5U) with
a modeled peptide (left) and CHD4-PHD2 struc-
ture (2L75) with H3K9me3 peptide (right).
(C) Peptide pull-down assays with biotinylated
histone peptides and recombinant tandem PHD
fingers of Chd5 containing single amino acid
mutations D346A, D361A, or D434A. Whereas the
Chd5-PHD mutant D346A binds the H3K4me0
peptide, mutants D361A and D434A have
compromised binding.
(D) FP measurements for GST-cleaved WT and
mutant PHDs binding to unmodified H3 (1-21)-
fluorescein peptides, represented as plots of
average anisotropies of two or more experiments
versus protein concentration. D361A and D434A
disrupt the interaction with the H3K4me0 peptide,
whereas D346A retains H3K4me0 binding. Error
bars denote SEM.
(E) H3 peptide pull-down assays with nuclear
extracts prepared from MEFs expressing Flag-
tagged WT Chd5 or the Chd5-PHD mutants,
followed by immunoblotting with an anti-Flag
antibody, indicate that whereas the WT Chd5 and
the Chd5-D346A mutant are pulled down by H3
peptide, the Chd5-D361A and D434A mutant
proteins are not.
See also Figure S2.Chd5 to transcriptionally modulate its targets, including genes
that have been implicated in Wnt signaling, chromatin remodel-
ing, and cell-cycle regulation, highlighting Chd5’s role in path-
ways that were previously implicated in tumor suppression
(Hers et al., 2011; Musgrove et al., 2011; Yadav et al., 2009;
Yao et al., 2011).
The Inability of Chd5-PHD Mutants to Bind H3 Causes
Oncogenic Transformation and Robust Tumorigenesis
In Vivo
The above findings indicate that PHD-mediated H3 binding is
essential for Chd5 to inhibit proliferation and to transregulate
genes encoding components of cancer-associated pathways.
We next investigated the extent to which perturbation of the
PHD-mediated Chd5-H3 interaction leads to cancer. We previ-
ously reported that Chd5-compromised MEFs were sensitized
to oncogenic transformation and thus predisposed to tumori-Cell Reports 3, 92–10genesis in vivo (Bagchi et al., 2007).
Therefore, we assessed whether cells
expressing functionally compromised
Chd5-PHD mutants were prone to Ras-
induced transformation and tumorigen-
esis in vivo. rtTA MEFs coexpressing
RasG12D and dox-inducible constructs
encoding WT or mutant versions ofChd5 were injected subcutaneously into two cohorts of athymic
nude mice. One cohort of mice received regular food, whereas
the other cohort received a dox-containing diet to induce
expression of WT Chd5 or the Chd5-PHD mutants, and
tumorigenesis was monitored (Table S5). Whereas expression
of WT Chd5 did not lead to tumor formation, cells expressing
mutant Chd5 formed tumors with a severity that correlated
inversely with their ability to bind H3, i.e., D361A and D434A
caused robust tumor development, and fewer and significantly
smaller tumors formed in response to D346A (Figures 3D and
S3F). Furthermore, tumors that arose from MEFs expressing
Chd5-PHD mutants that cannot bind H3 (D361A and D434A)
expressed Chd5 target genes at higher levels relative to the
smaller tumors that developed from MEFs expressing WT
Chd5 or D346A (Figure 3E). These findings demonstrate that
perturbation of the Chd5-H3 interaction dramatically enhances
tumorigenesis in vivo.2, January 31, 2013 ª2013 The Authors 95
Figure 3. Abrogation of PHD-Mediated Chd5-H3 Binding Causes an Inability to Inhibit Proliferation, Transcriptional Derepression, and
Tumorigenesis In Vivo
(A) Proliferation of MEFs expressing Chd5 or PHD mutants. Induction of WT Chd5 and the Chd5-PHD1-D346A mutant inhibits cellular proliferation, whereas
Chd5-PHD1-D361A, Chd5-PHD2-D434A, and Chd5-PHD1-D346A/PHD2-D434A fail to do so. MEFs expressing dox-inducible WT Chd5 or PHD mutants dox-
treated (+dox, blue squares) or untreated (dox, red circles) are quantitated. Data are represented as mean ± SD. Student’s two-tailed t test (*p = 2.4E-07 and
**p = 4.02E-06).
(B) Chd5-bound loci encode proteins involved in cancer pathways. The Kyoto Encyclopedia of Genes andGenomes (KEGG) and Ingenuity Pathway Analysis were
used to classify Chd5-bound genes.
(legend continued on next page)
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The Chd5-H3 Interaction Is Essential for Inhibition
of Proliferation, Induction of Differentiation,
and Suppression of Tumor Growth of Human
Neuroblastoma Cells
Given that CHD5 inactivation has been implicated in a variety of
human cancers, including neuroblastomas (Fujita et al., 2008;
Garcia et al., 2010, 2012), we asked whether induction of WT
ormutant Chd5 in a CHD5-deficient context could enforce tumor
suppression in human cancer cells. We chose the human neuro-
blastoma cell line SK-N-AS, which has a 1p36.33-1p36.2 dele-
tion (Kaghad et al., 1997) encompassing the CHD5 locus.
Endogenous CHD5 is absent or expressed at very low levels in
this cell line (Figure S4A; Garcia et al., 2010). To establish SK-
N-AS cells in which we could express Chd5 in a regulated
fashion, we generated SK-N-AS cells that stably express rtTA,
and introduced dox-inducible WT or mutant versions of Chd5
using retroviral infection (Figures S4B and S4C). Although induc-
tion of both WT Chd5 and D346A inhibited proliferation (Fig-
ure 4A), we observed only an 17% reduction, compared with
the striking 54% inhibition of proliferation in MEFs (see Fig-
ure 3A). This finding is consistent with the fact that p53, a down-
stream effector of Chd5-mediated tumor suppression (Bagchi
et al., 2007), is inactivated in SK-N-AS cells (Goldschneider
et al., 2006). Interestingly, human neuroblastoma cells express-
ingWT Chd5 had differentiated features, such as a flat epithelial-
like morphology and increased expression of the neuronal
marker MAP2, which contrasted markedly with the phenotype
of cells expressing either control vector or the H3 binding-
impaired PHD mutants (Chd5-D361A or Chd5-D434A), which
had the classic stem-like neuroblastoma morphology with prolif-
erative foci and lower expression of MAP2 (Figures 4B and S4D).
Cells expressing the Chd5-D346A mutant had a partially differ-
entiatedmorphology. This analysis indicated that PHD-mediated
H3 binding is essential for Chd5 to inhibit proliferation and to
induce differentiation of human neuroblastoma cells.
To assess the tumorigenic potential of Chd5-expressing
human neuroblastoma cells, we injected cells subcutaneously
into two different cohorts of athymic nude mice: one receiving
normal food and one receiving dox-containing food (Table S6;
Figure S4E). Whereas expression of WT Chd5 resulted in an
30% reduction in overall tumor volume, expression of the
H3-binding-compromised Chd5-PHD mutants (Chd5-D361A or
Chd5-D434A) failed to reduce tumor growth, and instead
enhanced overall tumor volume by 30%–50% (Figures 4C and(C) Chd5 transcriptionally represses target gene expression, whereas H3-binding
enhanced (WT+) or compromised (Chd5-KD) Chd5, vector control, or expressin
mutant D346A repress target gene expression, Chd5 PHD mutants that are un
normalized with actin, presented as mean ± SD. Fold change was calculated b
two-tailed t test (p value < 0.001).
(D) Chd5 PHD mutants that cannot bind H3 form robust tumors in vivo. MEFs ex
were injected subcutaneously into athymic nude mice, and tumor formation was
was provided in the diet. Kinetics of tumor growth of untreated (red circles) and tre
Although some injection sites developed lesions, these lesions were extremely sm
See Table S5 for detailed tumor data.
(E) Tumors developing from cells expressing Chd5 PHD mutants (D361A and D
qRT-PCR. Data were normalized with actin, and the fold change was derived by c
Chd5. Data are presented as mean ± SEM.
See also Figure S3, Table S3, and Table S4.4D). This demonstrates that induction of WT Chd5 suppresses
tumorigenesis in vivo.
DISCUSSION
Since the time that CHD5 was first reported as a tumor
suppressor mapping to human 1p36 (Bagchi et al., 2007), its
inactivation has been documented in a diverse array of human
cancers (Agrawal et al., 2011; Berger et al., 2011; Gorringe
et al., 2008; Jones et al., 2010; Koyama et al., 2012; Lang
et al., 2011; Li et al., 2011; Mokarram et al., 2009; Mulero-Nav-
arro and Esteller, 2008; Okawa et al., 2008; Robbins et al.,
2011; Cancer Genome Atlas Research Network, 2011; Wang
et al., 2009b; Zhao et al., 2011), which indicates that CHD5 regu-
lates processes that are fundamental for cancer prevention.
Therefore, defining how CHD5 protects against tumorigenesis
may affect the treatment of a variety of human cancers. Although
it belongs to a protein family that includesmembers implicated in
chromatin remodeling, the mechanism by which CHD5 exerts its
tumor-suppressive role has been largely unexplored. Here, we
demonstrate that the ability of Chd5 to bind unmodified H3 is
essential for tumor suppression.
By focusing on the mechanism by which CHD5 interacts with
chromatin, we discovered that the tandem PHDs mediate
binding to N-terminally unmodified H3. PHDs are modules that
were initially identified in plant homeodomain (PHD) proteins;
subsequently, PHD-containing proteins were discovered in
yeast, flies, and humans, especially in chromatin-associated
and nuclear proteins. Although the zinc-binding motifs of PHD
motifs are well conserved, diversity in the ligand-binding resi-
dues generates versatility in their interaction partners. PHDs
are histone readers that control gene expression cascades by
recruiting multiprotein complexes consisting of chromatin regu-
lators and transcription factors. Many PHDs specifically bind the
N terminus of H3, with different PHDs recognizing H3K4me2/3
versus H3K4me0, H3R2me0 versus H3R2me2, methylation at
H3K9 or H3K36, or acetylation at H3K14 (Sanchez and Zhou,
2011). Our findings are in agreement with a recent report (Oliver
et al., 2012) demonstrating that PHDs of CHD5 are most homol-
ogous to H3K4me0-readers, including those of the BRAF35-
HDAC complex protein BHC80 (Lan et al., 2007), Autoimmune
Regulator (AIRE; Koh et al., 2008; Org et al., 2008), Tripartite
Motif-containing protein 24 (TRIM24) (Tsai et al., 2010), DNA
(cytosine-5)-Methyltransferase 3-like protein (DNMT3L) (Ooimutants fail to do so. qRT-PCR analyses of RNA derived fromMEFs with either
g Chd5-PHD mutants indicates that whereas both WT Chd5 and Chd5 PHD
able to bind H3 (D361A, D434A, and D346A/D434A) fail to do so. Data were
y comparing MEFs with (+) and without () dox. Asterisk indicates Student’s
pressing RasG12D and either dox-inducible WT Chd5 or Chd5 PHD mutants
monitored. Y axis denotes tumor volume; X axis denotes the days after dox
ated (blue squares) mice are shown, with data represented as mean ± SD. (NB:
all [*]. The large tumor made it necessary to sacrifice this mouse at day 26 [**]).
434A) have derepression of Chd5 target genes. Tumor RNA was analyzed by
omparing tumors with the small lesion that developed in MEFs expressing WT
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Figure 4. TheChd5-H3 Interaction Is Essential for Chd5 to Inhibit Proliferation, InduceDifferentiation, and Suppress Tumor Growth of Human
Neuroblastoma Cells In Vivo
(A) Proliferation of SK-N-AS cells expressing rtTA together with either WT Chd5 or the PHD mutants. Induction of WT Chd5 and the Chd5-PHD1-D346A mutant
inhibits cellular proliferation, whereas no such effects are observed with an additional mutation in D434A or with Chd5-PHD1-D361A mutants. MEFs expressing
dox-inducible WT Chd5 or PHDmutants treated with dox (+dox, blue squares) or not treated (dox, red circles) are quantitated. Data are represented as mean ±
SD. Y axis denotes cell numbers; X axis denotes the days after dox treatment. Student’s two-tailed t test (*p = 0.004; **p = 0.008).
(B) Morphology (upper panel) and immunofluorescence staining showing expression of the neuron-specific differentiation marker MAP2 (lower panel) of human
neuroblastoma cells (SK-N-AS) expressing vector control, Chd5, or PHD mutants. SK-N-AS cells expressing WT Chd5 acquire a differentiated cellular
morphology and a corresponding increase in MAP2 expression compared with vector or Chd5-PHDmutant expressing SK-N-AS cells, which grow as polygonal
cells in focal clusters. Cells expressing the D346A mutant have an intermediate differentiation phenotype. Scale bar: 100 mm.
(C) Expression of WT Chd5 in SK-N-AS cells reduces tumorigenesis in vivo much more efficiently than does expression of vector or the Chd5 PHD mutants that
are defective in H3 binding. SK-N-AS cells expressing dox-induced control vector, WT Chd5, or Chd5-PHD mutants were injected subcutaneously into athymic
(legend continued on next page)
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et al., 2007), and CHD4 (Mansfield et al., 2011; Musselman et al.,
2009, 2012). These PHDs lack the aromatic cage characteristic
of PHDs that specifically bind H3K4me2/3.
We identified key residues of Chd5 PHDs that are conserved
among the close family members Chd3 and Chd4, and are
essential for mediating the H3 interaction. Mutation of these
residues (D361 in Chd5-PHD1, as well as D415 or D434 in
Chd5-PHD2) abrogates the Chd5-H3 interaction, compromising
Chd5’s cellular role in inhibiting proliferation, inducing differenti-
ation, and suppressing tumorigenesis. Perturbation of H3K4me0
PHD readers has been associated with several humanmalignan-
cies. For example, mutations in AIRE are associated with auto-
immune polyendocrinopathy-candidiasis-ectodermal dystrophy
(Koh et al., 2008; Org et al., 2008), and TRIM24 expression corre-
lates inversely with survival of breast cancer patients (Tsai et al.,
2010). Our findings herein define Chd5 as an H3-interacting
protein and provide a functional link between the CHD class of
H3K4me0 PHD readers and suppression of tumorigenesis.
Previous work indicated that CHD5 facilitates expression of
a tumor-suppressive network that includes p16 and p19 en-
coded by the Cdkn2a locus (Bagchi and Mills, 2008; Bagchi
et al., 2007). Whereas Chd5 loss enhances proliferation by
compromising expression of p16/Rb and p19/p53-mediated
tumor-suppressive pathways, gain of the genomic interval en-
compassing Chd5 compromises proliferation by excessively
activating these pathways. Excessive activation of p16/Rb
and p19/p53-mediated tumor-suppressive pathways causes
apoptosis, cellular senescence, and neonatal death, which are
dependent on p16, p19, and p53. Here, we demonstrate for
that inducible expression of WT Chd5 inhibits proliferation, but
mutant versions of Chd5 that are not able to bind H3 fail to do
so. We found that in addition to binding Cdkn2a, Chd5 binds
and regulates the expression of multiple loci across the genome,
the majority of which lack the active H3K4me3 mark that we
found abrogates Chd5 binding in vitro. The finding that Chd5
peaks are often upstream of adjacent H3K4me3 peaks suggests
that Chd5 binding facilitates the recruitment of additional protein
complexes that deposit the H3K4me3 mark, which is character-
istic of transcriptionally active genes. While our findings extend
our previous studies that first linked Chd5 to Cdkn2a (Bagchi
et al., 2007), here we show that an extensive number of addi-
tional cancer-associated loci are bound and regulated by
Chd5. These include genes encoding proteins that have been
implicated in chromatin dynamics and cancer-associated path-
ways. Thus, in addition to regulating Cdkn2a, a pivotal locus in
tumorigenesis, Chd5 modulates the expression of multiple
genes that regulate pathways that impinge upon the tumorigenic
process.
The finding that CHD5 status is a prognostic indicator of
survival following anticancer therapy for gallbladder carcinoma,
neuroblastoma, and ovarian cancer (Du et al., 2012; Garcianude mice, and tumor formation was monitored. The Y axis denotes the fold incr
treated with dox (blue) are shown. Data are represented as mean ± SEM.
(D) Percentage change of tumor growth in dox-treated mice compared with untre
expression of Chd5-PHD mutants D361A and D434A results in a 30%–50% in
See also Figure S4 and Table S6.et al., 2010; Koyama et al., 2012; Wong et al., 2011) suggests
that CHD5-modulated pathways are effective targets for anti-
cancer therapies. The heterozygous nature of CHD5 mutations
in human cancer raises the possibility that therapies that induce
expression of WT CHD5 could enforce tumor suppression. To
address this issue, it will be important to determine the extent
to which the WT allele is silenced by DNA methylation in human
cancers. Our finding that expression of mutant versions of Chd5
defective in H3 binding has a dominant negative effect on endog-
enous Chd5/CHD5, leading to enhanced tumorigenesis reminis-
cent of Chd5 loss, cautions that effective therapeutic strategies
will need to specifically induce expression of WT but not mutant
versions of CHD5. In addition, CHD5 levels must be carefully
controlled to avoid deleterious effects, as even one extra copy
of Chd5 causes excessive apoptosis and embryonic lethality
(Bagchi et al., 2007). Given our finding that tumor growth could
be inhibited in human neuroblastoma cells even in the context
of p53 deficiency, it is likely that CHD5’s multifaceted ways to
enforce tumor suppression will prove useful for regulating
diverse types of cancers, including those that involve combina-
tions of genetic lesions. The fact that CHD5 is a member of the
Trithorax-group (TrxG) proteins, which oppose Polycomb-
group (PcG)-mediated gene expression cascades (Mills, 2010),
suggests that strategies that inhibit PcG-mediated chromatin
dynamics could enforce CHD5 activity effectively without the
deleterious effects of inducing apoptosis or cellular senescence.
Our finding that Chd5 inhibits expression of the oncogenic PcG
protein Bmi1 indicates that Chd5 inhibits PcG-mediated chro-
matin dynamics at multiple levels.
In summary, this work defines a specific histone mark that
is bound by Chd5 and is required for its ability to regulate tran-
scriptional cascades, inhibit proliferation, induce differentiation,
and efficiently suppress tumorigenesis in vivo. These findings
implicate Chd5 as a member of the newly appreciated class of
unmodified H3-binding proteins, and provide mechanistic
insight into Chd5-mediated tumor suppression.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Retroviral Expression System
Mouse Chd5 cDNA from KK DNAFORM and Geneservice Ltd (Clone ID:
M5C1079M20) was used as a template for generating PCR products to clone
the PHDs and the full-length Chd5 cDNA. The PHDs were cloned into pGEX-
6P1 (Clontech). The dox-inducible retroviral expression systemwas generated
by cloning full-length Chd5 into pmCherry-C1 (Clontech) at the BglII/SalI
restriction site, removing cherry-Chd5 by NheI/SalI cleavage, and ligating to
a XbaI/XhoI-cut modified version of TtRMPV-PGK-HygroR (Zuber et al.,
2011) or TtRMPV-PGK-PuroR plasmid (see Figure S3A). The pMSCV-GFP-
IRES-mNrasG12D plasmid (Zuber et al., 2009) was provided by S. Lowe. Muta-
tions were generated by site-directed mutagenesis, and all plasmids were
confirmed by sequencing. The small hairpin RNA (shRNA) construct used for
knocking down Chd5 (shChd5-WZ) was cloned into the MLP retroviral vector.
Retroviral infection is described in the Extended Experimental Procedures.ease of tumor volume over a 17-day period. Mice that were untreated (red) or
ated mice. Expression of WT Chd5 reduces tumorigenesis by 31%, whereas
crease in tumorigenesis.
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Antibodies
Anti-Chd5 (M-182: sc-68389 [Santa Cruz] and in-house-raised polyclonal anti-
body Chd5-232), anti-H3K4me3 (07-473; Millipore), anti-H3K9me3 (07-442;
Millipore), normal rabbit IgG (2729; Cell Signaling), anti-histidine (631212;
Clontech), anti-b-actin (A5441; Sigma), and anti-MAP2 (ab11267; Abcam)
were used.
Recombinant Protein Production and Purification
Chd5-PHD glutathione S-transferase (GST) fusion proteins were produced by
inducing 1–2 L of bacterial cultures (in Luria Bertani [LB] medium containing
50 mM zinc chloride) with 0.1 mM IPTG (A600 = 0.6), followed by a 14 hr incu-
bation at 18C. Bacterial pellets were lysed in 100 mM Tris pH 7.5, 400 mM
NaCl, 5 mM dithiothreitol (DTT), 0.1 mg/ml lysozyme, and protease inhibitor
tablets (Roche), and cleared lysates were treated with polyethyleneimine
before purification. The GST-PHDs were purified by binding with gluta-
thione-agarose (Sigma) and eluted with reduced glutathione (Sigma). The
eluate was dialyzed in 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM DTT
overnight and used for biochemical assays. On-column cleavage of GST
was performed with PreScission Protease (GE Healthcare), and GST-cleaved
purified PHD was dialyzed with assay buffer.
In Vitro Histone Peptide Array, Peptide Pull-Down, and Fluorescence
Polarization Assays
Peptide microarray experiments were performed as previously described (Koh
et al., 2008). Biotinylated-peptide pull-down assays using recombinant
proteins were performed as previously described (Shi et al., 2006). C-terminal
biotinylated peptides (Table S8) were purchased from Millipore. Pull-down
assays using nuclear extracts prepared from WT mouse brain using the
Dignam protocol (Dignam et al., 1983) were performed as previously described
(Wysocka et al., 2006) with some modifications. Briefly, brains were dissected
from C57BL/6 mice, crushed in liquid nitrogen, and lysed according to the
Dignam protocol. Nuclear extracts were precleared with streptavidin beads
(Amersham) and incubated with peptide that had been prebound to streptavi-
din beads for 3 hr at 4C in binding buffer (20 mM HEPES, pH 7.9 at 4C, 20%
glycerol, 0.15 MKCl, 0.5 mMDTT, 0.2% (v/v) Triton X-100, and protease inhib-
itor). Approximately 5 mg of peptide was used per pull-down. Beads were
washed eight times and the bound proteins were subjected to Coomassie
staining and western blot analyses.
Fluorescence polarization (FP) experiments were carried out using a Biotek
Synergy 4 plate reader (Biotek) at 30C as previously described (Jacobs et al.,
2004). Fluorescein-labeled peptide (10 nM, synthesized as ARTKQTAR
KSTGGKAPRKQLAK-Flu; Peptide Protein Research Ltd.) was incubated for
30 min at 30C with varying amounts of purified GST-cleaved PHDs in binding
buffer (50 mM Tris, pH 7.0, 150 mM NaCl, 50 mM ZnCl2, 5 mM DTT).
Protein concentration was measured by absorbance spectroscopy (PHD:
ε280 = 23460 M1cm1; PHD1: ε280 = 15,845 M1cm1; PHD2: ε280 =
6,990 M1cm1). Peptide concentration was determined using absorbance
spectroscopy (extinction coefficient for fluoresceinated peptide ε492 =
68,000 M1cm1). Binding curves were analyzed using the anisotropy from
two or three independent experiments.
ChIP Assays and ChIP-Seq Analyses
Chromatin was prepared from WT MEFs and used for immunoprecipitation.
ChIP analyses were performed as described previously (Zeng et al., 2006)
with some modifications. For these analyses, 1 3 107 cells were used per
immunoprecipitation and were sequentially cross-linked with ethylene glyco-
lbis[succinimidyl succinate] (EGS; Thermo Scientific) for 30 m, followed by
1% formaldehyde for 10 m at room temperature. Cross-linking was quenched
with glycine, cells were washed and lysed, and chromatin was sheared by
sonication. Chromatin was immunoprecipitated with Dyna-beads preconju-
gated with primary antibodies specific for normal rabbit IgG, Chd5 (M-182),
or H3K4me3. The immunoprecipitated samples were washed and eluted,
and cross-linking was reversed with 200 mM NaCl for 8 hr. Samples were di-
gested with RNase A and treated with proteinase K before phenol/chloroform
extraction, and then used for ChIP-Solexa sequencing (performed at the CSHL
Genomics Shared Resource) or qPCR. Samples were analyzed in triplicate by
real-time PCR using SYBR green (Quanta Biosciences) on the LightCycler 480100 Cell Reports 3, 92–102, January 31, 2013 ª2013 The Authors(Roche). To allow comparison among primer sets, unprecipitated input
samples from each condition were serially diluted and used as standards for
all PCRs. The ChIP-Seq analysis is described in Extended Experimental
Procedures.
Cellular Assays
MEFs and SK-N-AS cells were assessed for proliferation by plating 5 3 104
cells and 2.5 3 104 cells on 6 cm dishes or six-well plates, respectively. Cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing
100 mg/ml Hygromycin B (Roche) and 0.5 mg/ml Puromycin (Sigma-Aldrich),
and were either untreated or treated with 0.2 mg/ml dox (Sigma). Cells were
harvested and each plate was counted in triplicate using a Z1 Coulter particle
counter (Beckman-Coulter) or crystal violet staining. Graphs and SEs were ob-
tained with Prism software. Tumorigenesis assays in athymic nude mice were
performed as previously described (Bagchi et al., 2007; Hemann et al., 2004).
Briefly, MEFs (0.5 3 106 cells) were injected subcutaneously into irradiated
athymic nude mice, and dox was administered in food and drinking water
(2 mg/ml) for 7 days and continued with dox only in food. Matrigel-mixed
1.63 106 SK-N-AS cells were injected subcutaneously into two cohorts of irra-
diated athymic nude mice. One group received a normal diet and the other
group received the dox diet 2 days prior to injections and continued on the
dox diet for the rest of the experiment. Tumor development was monitored
via measurements by a blinded observer, and tumors were harvested and
processed for subsequent analysis.
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